Q32 BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.02 USD | -0.78% |
|
+24.59% | +156.03% |
| Apr. 11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
| Apr. 03 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 334.3 | - | - |
| Enterprise Value (EV) 1 | 334.3 | 334.3 | 334.3 |
| P/E ratio | -6.41 x | -7.1 x | -6.59 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | -6.48 x | -5.46 x | -4.69 x |
| FCF Yield | -15.4% | -18.3% | -21.3% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 11,930 | - | - |
| Reference price 2 | 28.02 | 28.02 | 28.02 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -49.57 | -56.9 | -65.47 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -51.13 | -55.5 | -65.26 |
| Net income 1 | -53.74 | -51.13 | -55.5 | -65.26 |
| Net margin | - | - | - | - |
| EPS 2 | -7.410 | -4.370 | -3.945 | -4.255 |
| Free Cash Flow 1 | - | -51.61 | -61.26 | -71.31 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -11.95 | -12.24 | -12.54 | -12.85 | -13.68 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.92 | -11.71 | -12.06 | -12.44 | -13.68 |
| Net income 1 | -14.92 | -11.71 | -12.06 | -12.44 | -13.68 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.415 | -0.9800 | -1.005 | -1.035 | -0.8000 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -51.6 | -61.3 | -71.3 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2.67 | 2.81 | 3.42 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
28.02
USD
Average target price
47.5
USD
Spread / Average Target
+69.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +156.03% | 334M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- QTTB Stock
- Financials Q32 Bio Inc.
